Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided:	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.		n/a No commercial reagents

Cell materials	Yes (indicate where provided:	n/a
Cell lines: Provide species information, strain. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID		n/a No cell lines included in the study
Primary cultures: Provide species, strain, sex of origin, genetic modification status.		n/a No cell lines included in the study

Experimental animals	Yes (indicate where provided:	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID		n/a No animals included in the study
Animal observed in or captured from the field: Provide species, sex and age where possible		n/a No animals included in the study
Model organisms: Provide Accession number in repository (where relevant) **OR** RRID		n/a No animals included in the study

Plants and microbes	Yes (indicate where provided:	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild		n/a No plants included in the study
Microbes: provide species and strain, unique accession number if available, and source		n/a No animals included in the study

Human research participants	Yes (indicate where provided:	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Page 4, line 20-22 and Ethical Statement: Page 12, line 7-12	
Provide statement confirming informed consent obtained from study participants.		n/a It's a retrospective study
Report on age and sex for all study	Table 1	

Design

Study protocol	Yes (indicate where provided:	n/a
For clinical trials, provide the trial registration number **OR** cite DOI in		n/a No clinical

Laboratory protocol	Yes (indicate where provided:	n/a
Provide DOI or other citation details if detailed step-by-step protocols		n/a No protocols

Experimental study design	Yes (indicate where provided:	n/a
State whether and how the following have been done**, or** if they were not		
Sample size determination		n/a
Randomisation		n/a
Blinding		n/a
Inclusion/exclusion criteria	Page 4, line 14-18	

Sample definition and in-laboratory	Yes (indicate where provided:	n/a
State number of times the experiment was replicated in		n/a
Define whether data describe technical or biological replicates		n/a

Ethics	Yes (indicate where provided:	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s),	Page 4, line 20-22 and Ethical Statement: Page 12, line 7-12	
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide		n/a No animals included in the study
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none	Page 4, line 20-22 and Ethical Statement: Page 12, line 7-12	

Dual Use Research of Concern	Yes (indicate where provided:	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval		n/a No dual use research

Analysis

Attrition	Yes (indicate where provided:	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and	Page 4, line 14-18 (specified in advance)	

Statistics	Yes (indicate where provided:	n/a
Describe statistical tests used and justify choice of tests.	Page 5, line 37 to Page 6 line 11	

Data Availability	Yes (indicate where provided:	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.		n/a All data are included in the
If data are publicly available, provide accession number in repository or DOI or		n/a
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.		n/a

Code Availability	Yes (indicate where provided:	n/a
For all newly generated code and software essential for replicating the main findings		
State whether the code or software is		n/a
If code is publicly available, provide accession number in repository, or DOI or		n/a

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

Article Information: https://dx.doi.org/10.21037/tlcr-21-981